III Capital Management

III Capital Management is a New York-based alternative investment manager founded by Eytan Shapiro, who serves as Chief Investment Officer directing the firm's healthcare-focused investment strategy. Filing with the SEC under CIK #0001783139, the firm represents a specialized approach to life sciences and healthcare investing, leveraging deep scientific expertise and industry relationships to identify compelling opportunities across the biomedical landscape. The firm's foundation reflects Eytan Shapiro's extensive background in healthcare investing, which includes significant experience at prominent biotech-focused investment platforms. This pedigree informs III Capital Management's scientifically rigorous investment process, which emphasizes fundamental understanding of disease biology, clinical development pathways, and regulatory dynamics that drive value creation in healthcare securities. From its Manhattan headquarters, III Capital Management operates within the epicenter of healthcare finance, proximate to major pharmaceutical companies, academic medical centers, and the specialized investment banking and consulting resources essential to life sciences investing. This ecosystem positioning facilitates the expert network cultivation and scientific diligence that distinguish successful healthcare investors from generalist approaches. The firm's institutional investor base reflects the specialized nature of the healthcare-focused mandate. Allocators seeking dedicated life sciences exposure value the scientific depth and sector expertise that III Capital Management provides, capabilities difficult to replicate within generalist investment platforms lacking the requisite biomedical knowledge infrastructure.

III Capital Management employs a fundamentals-driven healthcare investment strategy anchored in rigorous scientific analysis. The approach emphasizes deep understanding of therapeutic mechanisms, clinical trial design, regulatory pathways, and commercial market dynamics that determine healthcare company outcomes. This scientific foundation distinguishes the firm's process from purely financial approaches to healthcare sector investing. The 13F Portfolio Composition reveals concentrated exposure across healthcare subsectors including biotechnology, pharmaceuticals, medical devices, and healthcare services. Position construction reflects conviction levels derived from scientific due diligence, with sizing calibrated to thesis confidence and risk/reward assessment. The portfolio's healthcare concentration represents a deliberate specialization strategy rather than diversified sector allocation. Biotechnology investments frequently anchor the portfolio, capitalizing on the sector's binary catalyst events and asymmetric return potential. Clinical trial readouts, FDA decisions, and partnership announcements create discrete value inflection points that fundamental analysis can anticipate and position around. Sector Allocation History demonstrates the firm's navigation across biotech subsectors—oncology, immunology, rare diseases, and emerging therapeutic modalities—based on scientific opportunity identification. The investment process integrates multiple analytical disciplines. Scientific experts evaluate therapeutic mechanisms and clinical probability of success, while financial analysis assesses valuation, market opportunity, and competitive positioning. This multidisciplinary approach addresses healthcare investing's unique challenge of requiring both scientific and financial expertise for successful security selection. Portfolio turnover maintains moderate levels, balancing conviction-driven holding periods against the tactical flexibility required to navigate healthcare's frequent catalysts. Clinical development timelines create natural position evolution as programs advance or encounter setbacks, driving portfolio changes based on updated scientific assessment rather than market timing considerations.

III Capital Management represents specialized access to healthcare and life sciences investing through the scientific expertise of founder Eytan Shapiro. The firm's New York base and institutional orientation position it as a credible allocator option for investors seeking dedicated biomedical sector exposure managed by professionals with deep domain expertise. The Historical Track Record derived from 13F-disclosed holdings illuminates the firm's healthcare investment process across market cycles. Analyzing position timing relative to clinical catalysts, therapeutic area allocation, and market cap distribution reveals the strategy's implementation characteristics. Healthcare specialist evaluation requires benchmark comparison against sector indices rather than broad market measures. Sharpe Ratio analysis contextualizes the strategy's risk-adjusted performance within healthcare investing's elevated volatility environment. Sector specialists accepting higher absolute volatility may nonetheless generate attractive risk-adjusted returns when performance is measured against appropriate healthcare benchmarks reflecting the opportunity set's inherent characteristics. Top 10 Holdings Concentration provides insight into the portfolio's conviction structure. Given the specialized mandate, major positions likely represent the highest-confidence therapeutic opportunities identified through the firm's scientific diligence process. Understanding these core holdings illuminates the investment team's views on the most compelling areas within healthcare. For allocators evaluating III Capital Management's approach, understanding healthcare investing's distinctive dynamics informs appropriate expectation setting. How does the firm's scientifically-grounded selection process navigate the binary clinical catalysts and regulatory events that distinguish healthcare returns from broader equity market patterns?

Healthcare sector concentration introduces distinctive Volatility Profile characteristics driven by binary clinical and regulatory events. Individual holdings may experience dramatic price movements around FDA decisions, clinical data releases, or competitive developments, creating return patterns with higher kurtosis than diversified strategies. This event-driven volatility represents an accepted aspect of healthcare specialist investing. Max Drawdown Depth analysis reveals sector-specific risk factors influencing portfolio performance. Biotech indices periodically experience significant corrections driven by clinical failures, regulatory setbacks, or sector rotation dynamics. The 2021-2022 period proved particularly challenging for growth-oriented biotech strategies as rising interest rates compressed valuations across the sector regardless of fundamental developments. Binary event risk pervades healthcare investing, particularly in biotechnology. Clinical trial failures can produce immediate, substantial losses in individual positions, though portfolio diversification across multiple therapeutic programs mitigates company-specific binary outcomes. Position sizing discipline calibrates exposure to individual binary events based on probability assessment and downside magnitude. The Downside Capture Ratio relative to broad equity benchmarks may diverge significantly given the healthcare concentration. During sector-specific corrections, the portfolio may underperform broader indices, while healthcare rallies may produce meaningful outperformance. This tracking error represents inherent sector specialist characteristics rather than risk management failure. Regulatory and political risk introduces additional volatility sources. Drug pricing debates, FDA policy changes, and healthcare reform proposals can impact sector valuations independent of company-specific fundamentals. III Capital Management's scientific expertise provides limited edge on political developments, representing systematic risks the strategy accepts.